Russell Investments Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $447K | Sell |
24,866
-111,706
| -82% | -$2.11M | ﹤0.01% | 2834 |
|
|
2026
Q1 | $2.97M | Sell |
136,572
-162,843
| -54% | -$3.15M | ﹤0.01% | 1647 |
|
|
2025
Q4 | $6.44M | Buy |
299,415
+131,121
| +78% | +$2.76M | 0.01% | 1160 |
|
|
2025
Q3 | $3.24M | Buy |
168,294
+62,019
| +58% | +$1.11M | ﹤0.01% | 1587 |
|
|
2025
Q2 | $1.82M | Buy |
106,275
+17,885
| +20% | +$763K | ﹤0.01% | 1769 |
|
|
2025
Q1 | $5.64M | Buy |
88,390
+16,705
| +23% | +$1.76M | 0.01% | 1098 |
|
|
2024
Q4 | $8.72M | Sell |
71,685
-53,411
| -43% | -$6.55M | 0.01% | 877 |
|
|
2024
Q3 | $15.6M | Buy |
125,096
+3,342
| +3% | +$462K | 0.02% | 666 |
|
|
2024
Q2 | $19.2M | Sell |
121,754
-5,675
| -4% | -$729K | 0.03% | 544 |
|
|
2024
Q1 | $16.5M | Buy |
127,429
+4,179
| +3% | +$512K | 0.03% | 626 |
|
|
2023
Q4 | $11.9M | Sell |
123,250
-7,315
| -6% | -$702K | 0.02% | 709 |
|
|
2023
Q3 | $15.8M | Sell |
130,565
-5,000
| -4% | -$565K | 0.03% | 554 |
|
|
2023
Q2 | $15.5M | Sell |
135,565
-22,602
| -14% | -$2.91M | 0.03% | 576 |
|
|
2023
Q1 | $21.8M | Buy |
158,167
+2,362
| +2% | +$306K | 0.04% | 471 |
|
|
2022
Q4 | $20.2M | Buy |
155,805
+10,064
| +7% | +$1.17M | 0.04% | 497 |
|
|
2022
Q3 | $16.1M | Buy |
145,741
+56,793
| +64% | +$5.72M | 0.04% | 563 |
|
|
2022
Q2 | $6.67M | Sell |
88,948
-9,168
| -9% | -$674K | 0.01% | 947 |
|
|
2022
Q1 | $7.66M | Buy |
98,116
+10,060
| +11% | +$770K | 0.01% | 938 |
|
|
2021
Q4 | $7.93M | Buy |
88,056
+58,758
| +201% | +$5.02M | 0.01% | 1018 |
|
|
2021
Q3 | $2.71M | Sell |
29,298
-3,514
| -11% | -$271K | ﹤0.01% | 1648 |
|
|
2021
Q2 | $2.55M | Sell |
32,812
-4,072
| -11% | -$309K | ﹤0.01% | 1767 |
|
|
2021
Q1 | $2.74M | Buy |
36,884
+20,884
| +131% | +$1.93M | ﹤0.01% | 1704 |
|
|
2020
Q4 | $2.73M | Sell |
16,000
-171
| -1% | -$25.3K | 0.01% | 1589 |
|
|
2020
Q3 | $2.27M | Sell |
16,171
-1,073
| -6% | -$163K | ﹤0.01% | 1603 |
|
|
2020
Q2 | $2.77M | Buy |
17,244
+1,247
| +8% | +$170K | 0.01% | 1448 |
|
|
2020
Q1 | $1.57M | Sell |
15,997
-700
| -4% | -$80K | ﹤0.01% | 1600 |
|
|
2019
Q4 | $2.15M | Buy |
16,697
+1,769
| +12% | +$179K | ﹤0.01% | 1696 |
|
|
2019
Q3 | $1.12M | Buy |
14,928
+915
| +7% | +$108K | ﹤0.01% | 1951 |
|
|
2019
Q2 | $2.13M | Sell |
14,013
-2,413
| -15% | -$293K | ﹤0.01% | 1644 |
|
|
2019
Q1 | $1.96M | Buy |
16,426
+1,399
| +9% | +$180K | ﹤0.01% | 1729 |
|
|
2018
Q4 | $1.64M | Sell |
15,027
-2,242
| -13% | -$280K | ﹤0.01% | 1704 |
|
|
2018
Q3 | $2.79M | Sell |
17,269
-32,398
| -65% | -$4.43M | 0.01% | 1587 |
|
|
2018
Q2 | $6.57M | Sell |
49,667
-2,876
| -5% | -$271K | 0.01% | 1142 |
|
|
2018
Q1 | $3.89M | Sell |
52,543
-2,546
| -5% | -$170K | 0.01% | 1494 |
|
|
2017
Q4 | $3.12M | Sell |
55,089
-26,321
| -32% | -$1.39M | 0.01% | 1592 |
|
|
2017
Q3 | $3.69M | Buy |
81,410
+6,240
| +8% | +$249K | 0.01% | 1426 |
|
|
2017
Q2 | $2.53M | Buy |
75,170
+36,897
| +96% | +$1.2M | ﹤0.01% | 1599 |
|
|
2017
Q1 | $1.13M | Buy |
38,273
+14,919
| +64% | +$462K | ﹤0.01% | 2031 |
|
|
2016
Q4 | $645K | Buy |
+23,354
| New | +$938K | ﹤0.01% | 2377 |
|
Other funds holding SRPT
EAM
Russell Investments Group's SRPT Position: Q2 2026 in Review
Russell Investments Group reduced its Sarepta Therapeutics (SRPT) stake by 82% in Q2 2026, selling an estimated $2.11M and leaving 24,866 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #2834.
Russell Investments Group first reported a position in SRPT in Q4 2016 and has held it in 39 quarters since. The position peaked at $21.8M in Q1 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Russell Investments Group held 24,866 shares of Sarepta Therapeutics worth $447K as of Q2 2026.
- Russell Investments Group sold 111,706 Sarepta Therapeutics shares in Q2 2026, an estimated $2.11M.
- Sarepta Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2834 holding.
- Russell Investments Group first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 39 quarters since.
- Russell Investments Group's Sarepta Therapeutics position peaked at $21.8M in Q1 2023.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.